Firefly Neuroscience Inc. (NASDAQ:AIFF) shares are up on Friday as the company continues to make strides in its development of brain scan technologies.
The surge follows a report on Wednesday detailing a significant expansion in its commercial footprint.
Firefly’s Commercial Footprint Expands 20-Fold
Firefly reported a remarkable 20-fold expansion of its commercial footprint and a staggering 33-fold increase in EEG/ERP brain scan volumes.
The company ended 2025 with partnerships with 99 commercial users, who completed over 10,800 EEG/ERP brain scans, marking year-over-year increases of 1,880% in partner sites and 3,227% in clinical assessments.
Additionally, Firefly's proprietary database now consists of over 191,000 EEG/ERP brain scans, making it the largest known standardized EEG/ERP repository.
CEO Greg Lipschitz emphasized that this growing foundation of clean data, combined with advanced NVIDIA Corp.’s (NASDAQ:NVDA) L40S GPU acceleration, positions the company for breakthroughs in cognitive brain biomarker discovery.
AIFF Shows Strong Short-Term Strength
The stock is currently trading 103.6% above its 20-day simple moving average (SMA) and 18.1% above its 100-day SMA, demonstrating short-term strength.
Over the past 12 months, shares have decreased by 63.40%, and they are currently positioned closer to their 52-week lows than highs.
The RSI is at 72.82, indicating that the stock is in overbought territory, which could suggest a potential pullback. Meanwhile, MACD is at 0.0411, above its signal line at -0.0517, indicating bullish momentum.
The combination of overbought RSI and bullish MACD suggests mixed momentum, indicating that while the stock is currently strong, caution may be warranted due to the overbought condition.
- Key Resistance: $2.00
- Key Support: $1.00
AIFF Price Action: Firefly Neuroscience shares were up 15.49% at $1.64 on Friday, according to Benzinga Pro data.
Image via Shutterstock
